|
Approved prescription condition respected, N (%)
| | | | |
|
FEV1 < 60% predicted1
|
53 (33.3%)
|
76 (63.3%)
|
28 (14.5%)
|
144 (60.5%)
|
|
History of repeated exacerbations
|
109 (68.6%)
|
51 (42.5%)
|
113 (58.5%)
|
55 (23.1%)
|
|
Continuous bronchodilator therapy
|
101 (63.5%)
|
97 (80.8%)
|
57 (29.5%)
|
89 (37.4%)
|
|
All conditions respected (regulatory approval criteria)
|
25 (15.7%)
|
31 (25.8%)
|
6 (3.1%)
|
16 (6.7%)
|
|
Details of conditions respected, N (%)
| | | | |
|
None
|
15 (9.4%)
|
6 (5.0%)
|
53 (27.5%)
|
47 (19.7%)
|
|
FEV1 only
|
5 (3.1%)
|
5 (4.2%)
|
9 (4.7%)
|
69 (29.0%)
|
|
Repeated exacerbations only
|
27 (17.0%)
|
2 (1.7%)
|
66 (34.2%)
|
13 (5.5%)
|
|
Continuous bronchodilator only
|
18 (11.3%)
|
28 (23.3%)
|
13 (6.7%)
|
28 (11.8%)
|
|
FEV1 and repeated exacerbations only
|
11 (6.9%)
|
10 (8.3%)
|
8 (4.1%)
|
20 (8.4%)
|
|
FEV1 and bronchodilators only
|
12 (7.5%)
|
30 (25.0%)
|
5 (2.6%)
|
39 (16.4%)
|
|
Repeated exacerbations and bronchodilators only
|
46 (28.9%)
|
8 (6.7%)
|
33 (17.1%)
|
6 (2.5%)
|
|
FEV1 and repeated exacerbations +/− bronchodilators
|
36 (22.6%)
|
41 (34.2%)
|
14 (7.3%)
|
36 (15.1%)
|
|
FEV1 or repeated exacerbations
|
126 (79.2%)
|
86 (71.7%)
|
127 (65.8%)
|
163 (68.5%)
|
|
N conditions respected, N (%)
| | | | |
|
At least one
|
144 (90.6%)
|
114 (95.0%)
|
140 (72.5%)
|
191 (80.3%)
|
|
At least two
|
94 (59.1%)
|
79 (65.8%)
|
52 (26.9%)
|
81 (34.0%)
|
